The Apex Times
Above the Noise
Business Wire
BusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessAmazon shares drop after FTC lawsuit alleges manipulation of advertising pricesThe Apex TimesBusinessApple CEO Handoff Keeps Hardware at Center Stage, With 72% of Sales Linked to Physical Products, Yahoo Finance ReportsThe Apex TimesBusinessAfter an unnamed event, a top-rated analyst outlines renewed confidence in Palantir as open-weight AI models come into focusThe Apex TimesBusinessCathie Wood’s funds sold about $74 million of AMD shares after a surge in earnings coverageThe Apex TimesBusinessAMD and Cisco link up on AI infrastructure in Saudi Arabia, lifting shares as details remain thinThe Apex TimesBusinessAdobe’s “$4 billion Saudi AI giveaway” spooks headlines, but investors shruggedThe Apex TimesBusinessBaird points to accelerating enterprise AI adoption as reason for bullish view on PalantirThe Apex TimesBusinessOracle’s Contracted Backlog Surpasses $600 Billion, Highlighting the Gap Between Promised Revenue and Market ValueThe Apex TimesBusinessExxon Mobil rises about 2% as oil rebounds, but misses a key Washington gas-price forumThe Apex TimesBusinessEnergy stocks lift as oil prices rise again, pulling Exxon Mobil and peers higherThe Apex TimesBusinessTim Cook’s Goodbye Note to Apple Staff Marks a 15-Year Run at the TopThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessAmazon shares drop after FTC lawsuit alleges manipulation of advertising pricesThe Apex TimesBusinessApple CEO Handoff Keeps Hardware at Center Stage, With 72% of Sales Linked to Physical Products, Yahoo Finance ReportsThe Apex TimesBusinessAfter an unnamed event, a top-rated analyst outlines renewed confidence in Palantir as open-weight AI models come into focusThe Apex TimesBusinessCathie Wood’s funds sold about $74 million of AMD shares after a surge in earnings coverageThe Apex TimesBusinessAMD and Cisco link up on AI infrastructure in Saudi Arabia, lifting shares as details remain thinThe Apex TimesBusinessAdobe’s “$4 billion Saudi AI giveaway” spooks headlines, but investors shruggedThe Apex TimesBusinessBaird points to accelerating enterprise AI adoption as reason for bullish view on PalantirThe Apex TimesBusinessOracle’s Contracted Backlog Surpasses $600 Billion, Highlighting the Gap Between Promised Revenue and Market ValueThe Apex TimesBusinessExxon Mobil rises about 2% as oil rebounds, but misses a key Washington gas-price forumThe Apex TimesBusinessEnergy stocks lift as oil prices rise again, pulling Exxon Mobil and peers higherThe Apex TimesBusinessTim Cook’s Goodbye Note to Apple Staff Marks a 15-Year Run at the TopThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessAmazon shares drop after FTC lawsuit alleges manipulation of advertising pricesThe Apex TimesBusinessApple CEO Handoff Keeps Hardware at Center Stage, With 72% of Sales Linked to Physical Products, Yahoo Finance ReportsThe Apex TimesBusinessAfter an unnamed event, a top-rated analyst outlines renewed confidence in Palantir as open-weight AI models come into focusThe Apex TimesBusinessCathie Wood’s funds sold about $74 million of AMD shares after a surge in earnings coverageThe Apex TimesBusinessAMD and Cisco link up on AI infrastructure in Saudi Arabia, lifting shares as details remain thinThe Apex TimesBusinessAdobe’s “$4 billion Saudi AI giveaway” spooks headlines, but investors shruggedThe Apex TimesBusinessBaird points to accelerating enterprise AI adoption as reason for bullish view on PalantirThe Apex TimesBusinessOracle’s Contracted Backlog Surpasses $600 Billion, Highlighting the Gap Between Promised Revenue and Market ValueThe Apex TimesBusinessExxon Mobil rises about 2% as oil rebounds, but misses a key Washington gas-price forumThe Apex TimesBusinessEnergy stocks lift as oil prices rise again, pulling Exxon Mobil and peers higherThe Apex TimesBusinessTim Cook’s Goodbye Note to Apple Staff Marks a 15-Year Run at the TopThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessAmazon shares drop after FTC lawsuit alleges manipulation of advertising pricesThe Apex TimesBusinessApple CEO Handoff Keeps Hardware at Center Stage, With 72% of Sales Linked to Physical Products, Yahoo Finance ReportsThe Apex TimesBusinessAfter an unnamed event, a top-rated analyst outlines renewed confidence in Palantir as open-weight AI models come into focusThe Apex TimesBusinessCathie Wood’s funds sold about $74 million of AMD shares after a surge in earnings coverageThe Apex TimesBusinessAMD and Cisco link up on AI infrastructure in Saudi Arabia, lifting shares as details remain thinThe Apex TimesBusinessAdobe’s “$4 billion Saudi AI giveaway” spooks headlines, but investors shruggedThe Apex TimesBusinessBaird points to accelerating enterprise AI adoption as reason for bullish view on PalantirThe Apex TimesBusinessOracle’s Contracted Backlog Surpasses $600 Billion, Highlighting the Gap Between Promised Revenue and Market ValueThe Apex TimesBusinessExxon Mobil rises about 2% as oil rebounds, but misses a key Washington gas-price forumThe Apex TimesBusinessEnergy stocks lift as oil prices rise again, pulling Exxon Mobil and peers higherThe Apex TimesBusinessTim Cook’s Goodbye Note to Apple Staff Marks a 15-Year Run at the TopThe Apex Times
Back to front
Eli Lilly’s Jaypirca (pirtobrutinib) gets a positive EU CHMP recommendation for chronic lymphocytic leukemia
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 26, 7:46 AM EDT

Eli Lilly’s Jaypirca (pirtobrutinib) gets a positive EU CHMP recommendation for chronic lymphocytic leukemia

A favorable opinion from the EMA’s CHMP puts Lilly’s Jaypirca one step closer to potential approval in the European Union for adults with chronic lymphocytic leukemia, covering all lines of therapy.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly is advancing its cancer drug Jaypirca (pirtobrutinib) toward a broader regulatory footprint in Europe after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion, according to a report published by Yahoo Finance on June 26, 2026.

The CHMP recommendation relates to use in adults with chronic lymphocytic leukemia, or CLL, a type of blood cancer. The proposed scope covers treatment across all lines of therapy, meaning the therapy is intended to be usable regardless of where a patient is in their treatment path, from earlier lines to later ones.

A positive CHMP opinion does not itself grant marketing authorization across the European Union. Instead, it is a formal step in the EMA process that is followed by a decision from the European Commission, which typically considers CHMP recommendations before issuing a final approval for EU-wide use.

Lilly did not provide additional details in the Yahoo Finance post beyond the CHMP’s positive opinion and the stated intended patient population and line-of-therapy coverage. The report also does not spell out trial datasets, endpoints, comparative results versus existing therapies, or any conditions that could be attached to approval.

For Lilly, the development matters because CLL remains a large and active oncology market in Europe, where therapy selection is increasingly influenced by how well drugs perform across different treatment settings. A label that spans all lines of therapy can simplify prescribing decisions and may position a treatment more broadly when clinicians are deciding between multiple available options.

More broadly, the CHMP opinion underscores the EMA’s ongoing approach to reviewing oncology medicines using standardized, evidence-based assessments through its medicinal product committees. For patients and physicians, CHMP recommendations can be a meaningful announcement that an application met the agency’s scientific and regulatory thresholds, even though the ultimate EU approval still depends on the European Commission’s follow-through.

Still, the regulatory picture is not complete. The Yahoo Finance report did not indicate whether the CHMP opinion includes any restrictions, confirmatory study requirements, or timing expectations for the European Commission decision. Without those details, it is not possible to determine how quickly Jaypirca could become available for the described CLL population across the EU or whether the final authorization could differ from the CHMP recommendation.

Why It Matters

  • If finalized by the European Commission, the CHMP recommendation could expand Jaypirca’s commercial opportunity in one of Europe’s major oncology disease areas.
  • A label that covers all lines of therapy can increase flexibility for clinicians, potentially improving the drug’s relevance across patient journeys.
  • The update provides an important regulatory milestone, though final authorization and any conditions still remain to be determined.
  • Investors and analysts will likely watch for the European Commission’s timing and whether the final label matches the CHMP scope.

Sources

Key Facts

  • Eli Lilly’s Jaypirca (pirtobrutinib) received a positive opinion from the EMA’s CHMP, according to a June 26, 2026 Yahoo Finance report.
  • The CHMP recommendation is for adults with chronic lymphocytic leukemia (CLL).
  • The recommended indication covers use across all lines of therapy.
  • A CHMP positive opinion is part of the EMA process and is followed by a European Commission decision for final EU authorization.
  • The report did not include trial results, endpoints, or any label restrictions or conditions in the disclosed text.

Healthcare Related

Eli Lilly’s Jaypirca (pirtobrutinib) gets a positive EU CHMP recommendation for chronic lymphocytic leukemia | The Apex Times